Onconephrology is a wide fast-growing and intricate field. Patients with cancer often develop kidney diseases that have distinct characteristics and require specialized treatment approaches. Cancer directly or indirectly damages the kidneys through the adverse effects of therapies. As molecular oncology continues to evolve, nephrologists are encountering new and partially unrecognized treatments involving targeted therapy agents that have adverse effects on the kidneys. When making informed decisions about prognosis and treatment options for both oncologic and renal disease, a nephrologist needs to have a good understanding of the patient’s preferences and goals. Data shows that patients with acute or chronic kidney disease tend to have worse outcomes and are less likely to respond to curative treatment regimens. With the current state of knowledge in cancer immunobiology as well as the emerging mechanisms behind the toxicity of oncotherapeutic drugs, it is essential for nephrologists to have a solid understanding of this field.
This issue wishes to cover what is clinically unique about onconephrology, including the pathophysiology and treatment of various cancer-associated kidney complications with a focus on acute kidney injury, chronic kidney disease, drug-induced nephrotoxicity of emerging therapies, kidney disease in stem cell transplantation, and electrolyte disorders.
This Research Topic will focus on different aspects of onconephrology and will provide insights for future research and clinical practices. Some possible themes are AKI in cancer patients, chemotherapy nephrotoxicity, CKD and chemotherapy, myeloma kidney and monoclonal gammopathy of renal significance, check point inhibitors nephrotoxicity, rechallenge and kidney transplantation, targeted therapies and kidney, CAR-T cell and cytokine release syndrome, and bone marrow transplantation associated AKI. We invite you to submit the most recent trends, developments, clinical practice, and challenges in these themes as original research papers, reviews, meta-analyses, systematic reviews, opinions, or perspectives papers.
Onconephrology is a wide fast-growing and intricate field. Patients with cancer often develop kidney diseases that have distinct characteristics and require specialized treatment approaches. Cancer directly or indirectly damages the kidneys through the adverse effects of therapies. As molecular oncology continues to evolve, nephrologists are encountering new and partially unrecognized treatments involving targeted therapy agents that have adverse effects on the kidneys. When making informed decisions about prognosis and treatment options for both oncologic and renal disease, a nephrologist needs to have a good understanding of the patient’s preferences and goals. Data shows that patients with acute or chronic kidney disease tend to have worse outcomes and are less likely to respond to curative treatment regimens. With the current state of knowledge in cancer immunobiology as well as the emerging mechanisms behind the toxicity of oncotherapeutic drugs, it is essential for nephrologists to have a solid understanding of this field.
This issue wishes to cover what is clinically unique about onconephrology, including the pathophysiology and treatment of various cancer-associated kidney complications with a focus on acute kidney injury, chronic kidney disease, drug-induced nephrotoxicity of emerging therapies, kidney disease in stem cell transplantation, and electrolyte disorders.
This Research Topic will focus on different aspects of onconephrology and will provide insights for future research and clinical practices. Some possible themes are AKI in cancer patients, chemotherapy nephrotoxicity, CKD and chemotherapy, myeloma kidney and monoclonal gammopathy of renal significance, check point inhibitors nephrotoxicity, rechallenge and kidney transplantation, targeted therapies and kidney, CAR-T cell and cytokine release syndrome, and bone marrow transplantation associated AKI. We invite you to submit the most recent trends, developments, clinical practice, and challenges in these themes as original research papers, reviews, meta-analyses, systematic reviews, opinions, or perspectives papers.
